{"id":"NCT00803634","sponsor":"The Medicines Company","briefTitle":"Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)","officialTitle":"A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2012-02","completion":"2012-03","firstPosted":"2008-12-05","resultsPosted":"2014-08-19","lastUpdate":"2014-08-29"},"enrollment":117,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension","Heart Failure"],"interventions":[{"type":"DRUG","name":"Clevidipine","otherNames":["Cleviprex","clevidipine emulsion","clevidipine injectible emulsion"]},{"type":"DRUG","name":"Standard of Care IV antihypertensive","otherNames":["nitroglycerin","nicardipine","sodium nitroprusside","isosorbide dinitrate","hydralizine","diltiazem"]}],"arms":[{"label":"Clevidipine","type":"EXPERIMENTAL"},{"label":"Standard of Care IV antihypertensive","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of intravenous (IV) clevidipine as compared with standard of care IV antihypertensive agents for blood pressure (BP) lowering in patients with acute heart failure and elevated BP.","primaryOutcome":{"measure":"Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes","timeFrame":"Initiation of study drug through the initial 30-minutes","effectByArm":[{"arm":"Clevidipine","deltaMin":15,"sd":null},{"arm":"Standard of Care","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":13,"countries":["United States","France","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":51},"commonTop":["Headache","Nausea","Insomnia"]}}